Efficacy and safety of eliapixant in refractory chronic cough: The randomized, placebo-controlled Phase 2b PAGANINI study

This randomized, double-blind, parallel-group, placebo-controlled, multicenter, dose-finding, Phase 2b study evaluated the efficacy and safety of eliapixant in 310 adult patients with refractory chronic cough. The primary endpoint was change from baseline in 24-hour cough count after 12 weeks of treatment. Secondary endpoints included: the proportion of patients with a ≥30% reduction from baseline in 24-hour cough count; change from baseline in hourly awake cough count; change from baseline in cough severity; and change from baseline in cough-related QoL. During the study, 24-hour cough count was monitored using the Vitalograph VitaloJAK device.